The classic razor-and-blade device: the giving-set contract matters more than the pump price. Sized from published research with a GCC and India lens, for buyers, suppliers and investors.
The classic razor-and-blade device: the giving-set contract matters more than the pump price. Published estimates normalised to 2025 range from USD 19.9 bn to USD 19.9 bn; the Consulting Wallah central estimate is USD 19.9 bn, growing at about 7% a year to USD 32.8 bn by 2032. Scope differences between publishers explain most of the spread — the comparison table below states each one.
Growth is driven by rising chronic disease prevalence: diabetes, cancer, cardiovascular (MarketsandMarkets; DataM); growth of ambulatory and home-care infusion settings (MarketsandMarkets; Meticulous); advances in smart infusion systems with dose-error-reduction software and connectivity (MarketsandMarkets).
Context that matters for buyers and suppliers: Global infusion pump market USD 19.9 bn in 2025, projected USD 28.3 bn by 2030 (7.4% CAGR). Accessories & consumables expected to be the largest product segment of the infusion pumps market in 2025. Middle East & Africa infusion pumps market USD 769.17 mn in 2024, 5.9% CAGR to 2033; syringe pumps dominate. BD estimated to hold ~55-60% of the US infusion pump market; Alaris used in care of 70% of US infusion-pump patients (2020).
The chart shows the Consulting Wallah central estimate: published figures normalised to 2025, median taken, and projected at the median published growth rate. The published range for 2025 is USD 19.9 bn–USD 19.9 bn; differences are mostly scope.
| Publisher (date) | Base value | Forecast | CAGR |
|---|---|---|---|
| MarketsandMarkets (2026-05) — global / infusion pumps incl. devices (insulin, syringe, vol | USD 19.9 bn (2025) | USD 28.3 bn (2030) | 7.4% |
| Meticulous Research (2024-07) — global / infusion pumps; accessories & consumables expected | None () | USD 25.9 bn (2032) | 8.3% |
| DataM Intelligence (2025-12) — region / Middle East & Africa infusion pumps; syringe infusi | USD 769.17 mn (2024) | USD 1,279.37 mn (2033) | 5.9% (2025-2033) |
| IndustryARC (via IPS News) (2020-07) — region / MEA infusion therapy devices (older 2020 publicatio | None () | USD 560.27 mn (2025) | — |
| Consulting Wallah central estimate | USD 19.9 bn (2025) | USD 32.8 bn (2032) | ~7% |
Source: Publisher pages as listed under Sources; CW estimate as described in Method.
Included: the product category as named, across hospital, clinic, laboratory and home settings, including the consumables and service contracts that travel with it where sources report them together. Excluded: adjacent categories reported in their own markets. Global figures are quoted as published; regional figures are flagged by scope.
Shares as reported by the named sources; ranking is more reliable than the exact percentage.
| Segment | Share | Note | |
|---|---|---|---|
| BD (Alaris) | 60% | Alaris used in care of 70% of US patients on infusion pump therapy (BD, 2020) |
Source: MedTech Dive
| Axis | Segment | Figure | Note |
|---|---|---|---|
| By product type | Accessories & consumables (administration sets, dedicated/non-dedicated) | largest share (no % given) | Meticulous: largest product segment 2025; MnM: accessories & consumables larger than other type in 2024 — basis of razor/blade lock-in |
| By product type | Devices (volumetric, syringe, insulin, enteral, PCA) | largest among device categories per MnM 2024 | |
| By product type | Syringe pumps | expected to dominate MEA | DataM Intelligence |
| By product type | Multi-channel pumps | largest channel segment | Meticulous |
| By application | Oncology | largest (no % given) | Meticulous |
| By application | Diabetes | expanding rapidly; hybrid closed-loop systems | MarketsandMarkets |
| By end user / region | Hospitals & clinics | largest end user | Meticulous |
| By end user / region | North America | largest region 2024/2025; US largest country | MarketsandMarkets; Meticulous |
| By end user / region | Europe, Asia-Pacific | 2nd and 3rd | Meticulous |
Source: As listed under Sources.
| Country / region | Figure | Year | Source |
|---|---|---|---|
| Middle East & Africa infusion pumps | USD 769.17 mn | 2024 | DataM Intelligence |
| Middle East & Africa infusion pumps | USD 1,279.37 mn | 2033 | DataM Intelligence |
| MENA adults with diabetes | ~73 mn (2021) rising to 135.7 mn by 2045 (IDF) | 2021 | DataM Intelligence citing IDF |
| Global infusion pumps | USD 19.9 bn | 2025 | MarketsandMarkets |
Source: Sources as named; see Sources and method.
Consulting Wallah works this market from both sides: hospital groups in the UAE, Saudi Arabia, India and Bangladesh as buyers, and manufacturers in India, China, Singapore, Malaysia and the US as suppliers through the Network. Our observation is that registration status, in-country stock and structured quotations decide access in the GCC, while price and distributor reach decide it in India. CW observation
Opportunities we see: emerging markets (Meticulous); ioT/specialty infusion systems and EHR-integrated smart pumps (Meticulous; MarketsandMarkets); oncology and diabetes applications, hybrid closed-loop systems (Meticulous; MarketsandMarkets).
| Date | Development | Source |
|---|---|---|
| 2023-07 | FDA granted BD 510(k) clearance for updated Alaris infusion system, allowing resumed distribution and remediation of installed base after recalls; BD held ~55-60% of US market | MedTech Dive |
| 2024-07 | Meticulous Research: infusion pumps market to reach USD 25.9 bn by 2032 at 8.3% CAGR; accessories/consumables largest segment | Meticulous Research |
| 2025-12 | DataM Intelligence update: MEA infusion pumps USD 769.17 mn (2024) to USD 1,279.37 mn (2033), 5.9% CAGR | DataM Intelligence |
| 2025-12 | Infusion pump market 2030 trends highlight flexible connectivity solutions (MarketsandMarkets release) | PharmiWeb |
| 2026-05 | MarketsandMarkets: infusion pump market USD 19.9 bn (2025) to USD 28.3 bn (2030), 7.4% CAGR, driven by smart technologies and home-based care | MarketsandMarkets |
Source: Company and press announcements as named.
Key companies named across the sources; local distributors and implementation partners matter as much as the brand in the GCC and India.
Published estimates normalised to 2025 range from USD 19.9 bn to USD 19.9 bn. Consulting Wallah’s central estimate is USD 19.9 bn in 2025, rising to about USD 32.8 bn by 2032.
Published CAGRs range from 7.4% to 7.4%; our central case is about 7% a year to 2032.
Becton Dickinson (BD / Alaris, CareFusion), Baxter International (Novum IQ, Sigma Spectrum), B. Braun Melsungen (Infusomat, Perfusor, Space), Fresenius Kabi (Agilia, Ivenix), ICU Medical (Plum, formerly Smiths Medical / Hospira), Shenzhen Mindray Bio-Medical (BeneFusion), Terumo, Nipro among others.
The summary on this page is free to read and share with attribution. The full report is free for hospital leaders and registered Consulting Wallah Network members, and priced on request for others.
The full report (PDF, 40 pages) adds the GCC and India deep-dives, hospital-level benchmarks from the Consulting Wallah Network and the full source tables. Free for hospital leaders and registered network members; otherwise priced on request.
How to read these figures. Published market-size estimates for this market vary widely because publishers define scope differently (software only vs software + services + logistics). Where we show a Consulting Wallah estimate we state the range of published figures it is triangulated from and our scope. Figures marked as reported are quoted from the named source. Nothing here is investment advice.